Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi (R) for the treatment of adults with polycythemia vera (PV). The Company is seeking a ropeginterferon alfa-2b-njft label ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Somapacitan, a long-acting human growth hormone analog, was evaluated in growth hormone treatment-naïve, pre-pubertal pediatric patients.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

In this video, Melissa Shoemaker, MD, MPH, compares oral GLP-1 medication to previous anti-obesity treatments.

By Hugo Francisco de Souza Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...

These Cornbread Hemp gummies have a higher potency and may include up to 4 milligrams (mg) of THC per gummy, so this brand is a great choice if you’re looking for a strong CBD gummy that doesn’t taste ...

Zepbound KwikPen, a 4-dose single-patient delivery device for tirzepatide administration has been made available by Lilly.

NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...